Man Group PLC Catalyst Pharmaceuticals, Inc. Transaction History

Man Group PLC

$54.1 Billion
Q3 2025

A detailed history of Man Group PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Man Group PLC holds 464,002 shares of CPRX stock, worth $10.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

464,002

Previous 430,904 7.68%

Holding current value

$10.8 Million

Previous $9.35 Million 2.25%

% of portfolio

0.02%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$19.13 - $22.22 $633,164 - $735,437	33,098 Added 7.68%	464,002 $9.14 Million
Q2 2025 Aug 14, 2025	BUY	$21.4 - $26.31 $2.89 Million - $3.56 Million	135,162 Added 45.7%	430,904 $9.35 Million
Q1 2025 May 15, 2025	SELL	$19.53 - $25.74 $392,064 - $516,730	-20,075 Reduced 6.36%	295,742 $7.17 Million
Q4 2024 Feb 14, 2025	BUY	$19.73 - $23.93 $1.21 Million - $1.46 Million	61,123 Added 24.0%	315,817 $6.59 Million
Q3 2024 Nov 14, 2024	SELL	$15.19 - $21.35 $3.27 Million - $4.59 Million	-215,150 Reduced 45.79%	254,694 $5.06 Million

Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $2.2 Million - $2.53 Million	-149,567 Reduced 24.15%	469,844 $7.28 Million
Q1 2024 May 15, 2024	SELL	$13.18 - $17.11 $326,929 - $424,413	-24,805 Reduced 3.85%	619,411 $9.87 Million
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $416,552 - $611,391	-35,361 Reduced 5.2%	644,216 $10.8 Million
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $1.82 Million - $2.33 Million	-155,431 Reduced 18.61%	679,577 $7.94 Million
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $745,372 - $1.17 Million	-64,815 Reduced 7.2%	835,008 $11.2 Million
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $147,572 - $216,625	10,291 Added 1.16%	899,823 $14.9 Million
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $1.25 Million - $2 Million	102,432 Added 13.01%	889,532 $16.5 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $3.41 Million - $7.49 Million	482,300 Added 158.23%	787,100 $10.1 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $303,401 - $417,359	48,700 Added 19.02%	304,800 $2.14 Million
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $726,408 - $1.14 Million	-136,800 Reduced 34.82%	256,100 $2.12 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $453,270 - $648,150	87,000 Added 28.44%	392,900 $2.66 Million
Q2 2021 Aug 16, 2021	SELL	$4.29 - $6.05 $250,222 - $352,878	-58,327 Reduced 16.01%	305,900 $1.76 Million
Q1 2021 May 17, 2021	SELL	$3.45 - $4.69 $2.17 Million - $2.95 Million	-629,335 Reduced 63.34%	364,227 $1.68 Million
Q4 2020 Feb 16, 2021	SELL	$2.97 - $3.83 $420,255 - $541,945	-141,500 Reduced 12.47%	993,562 $3.32 Million
Q3 2020 Nov 16, 2020	BUY	$2.97 - $5.08 $253,421 - $433,461	85,327 Added 8.13%	1,135,062 $3.37 Million
Q2 2020 Aug 14, 2020	BUY	$3.48 - $5.05 $3.28 Million - $4.75 Million	941,435 Added 869.28%	1,049,735 $4.85 Million
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $90,045 - $179,745	34,500 Added 46.75%	108,300 $417,000
Q4 2019 Feb 18, 2020	BUY	$3.67 - $5.7 $270,846 - $420,660	73,800 New	73,800 $277,000

Others Institutions Holding CPRX

# of Institutions

394

Shares Held

106M

Call Options Held

164K

Put Options Held

439K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.38B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account